Diagnostic Value and Safety of Combined Biopsy for Mediastinal Metastasis of Lung Cancer
Recruiting · NCT07488507 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
EBUS-TBMCB
What this trial is about
The study is aimed o evaluate the diagnostic performance and treatment guidance of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) combined with transbronchial mediastinal cryobiopsy (EBUS-TBMCB) in patients with mediastinal metastases of lung cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Aged ≥18 years;
- Presence of at least one mediastinal lesion (short-axis diameter ≥10 mm) confirmed by thin-slice chest CT;
- Patients who have not undergone prior mediastinal biopsy and require further mediastinal biopsy to confirm etiology or pathological subtype, meeting at least one of the following criterias:
- suspected lung cancer diagnosed by two senior physicians; (2) confirmed lung cancer (requiring mediastinal staging); (3) recurrent lung cancer; 4.Patients must have completed all required preoperative laboratory tests and necessary examinations (e.g., cardiac ultrasound, CTA) to rule out contraindications; 5. Patients are informed and capable of providing written informed consent.
Exclusion criteria
- Presence of severe cardiopulmonary disease, coagulation disorders, massive hemoptysis, poor tolerance to anesthesia, or other contraindications related to bronchoscopy;
- Intraoperative endobronchial ultrasound exploration of the lesion failed to detect the target lesion despite \> 20 minutes of attempts;
- Lesions identified as abscesses or cysts;
- Presence of mental illness, severe neurosis, or other conditions that preclude the provision of informed consent;
- Patients who have participated in other clinical trials within 3 months;
- Any other conditions considered to be inappropriate to be involved in this trial.
Where it is running
1 location listed.
- Third Military Medical University - Chongqing, Chongqing Municipality, China